http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 20 Dec 2024 08:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Altamira+Therapeutics+++++For%3A+Dec+20/24129749.html si-local-file:///var/storage/secattach/20241220/24129749.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Altamira+Therapeutics+++++For%3A+Dec+20/24129749.html Fri, 20 Dec 2024 08:00:00 -0500 CYTO O.40707706 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Altamira+Therapeutics+++++For%3A+Dec+20/24129749.html si-local-file:///var/storage/secattach/20241220/24129749.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Altamira+Therapeutics+++++For%3A+Dec+20/24129749.html Fri, 20 Dec 2024 08:00:00 -0500 CYTO O.40707706 http://www.streetinsider.com/SEC+Filings/Form++SC+13G+++++Altamira+Therapeutics++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/23984625.html si-local-file:///var/storage/secattach/20241114/23984625.html http://www.streetinsider.com/SEC+Filings/Form++SC+13G+++++Altamira+Therapeutics++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/23984625.html Thu, 14 Nov 2024 15:28:00 -0500 CYTO O.40707706 http://www.streetinsider.com/SEC+Filings/Form++SC+13G+++++Altamira+Therapeutics++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/23984625.html si-local-file:///var/storage/secattach/20241114/23984625.html http://www.streetinsider.com/SEC+Filings/Form++SC+13G+++++Altamira+Therapeutics++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/23984625.html Thu, 14 Nov 2024 15:28:00 -0500 CYTO O.40707706 http://www.streetinsider.com/Corporate+News/Altamira+Therapeutics+%28CYTO%29+Provides+Update+on+Nasdaq+Listing/23805142.html <p>Altamira Therapeutics Ltd. (Nasdaq: CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. The letter stated that the Company is not eligible for any cure period due http://www.streetinsider.com/Corporate+News/Altamira+Therapeutics+%28CYTO%29+Provides+Update+on+Nasdaq+Listing/23805142.html Fri, 04 Oct 2024 16:01:40 -0500 CYTO http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Altamira+Therapeutics+++++For%3A+Oct+04/23805139.html si-local-file:///var/storage/secattach/20241004/23805139.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Altamira+Therapeutics+++++For%3A+Oct+04/23805139.html Fri, 04 Oct 2024 16:01:00 -0500 CYTO O.40707706 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Altamira+Therapeutics+++++For%3A+Oct+04/23805139.html si-local-file:///var/storage/secattach/20241004/23805139.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Altamira+Therapeutics+++++For%3A+Oct+04/23805139.html Fri, 04 Oct 2024 16:01:00 -0500 CYTO O.40707706 http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing+/23805127.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing+/23805127.html Fri, 04 Oct 2024 16:01:00 -0500 CYTO CYTO http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing+/23805127.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing+/23805127.html Fri, 04 Oct 2024 16:01:00 -0500 CYTO CYTO http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing+/23805127.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing+/23805127.html Fri, 04 Oct 2024 16:01:00 -0500 CYTO CYTO http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing+/23805127.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing+/23805127.html Fri, 04 Oct 2024 16:01:00 -0500 CYTO CYTO http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html Fri, 04 Oct 2024 16:01:00 -0500 A.50202348 CYTO O.40707706 O.48270048 http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html Fri, 04 Oct 2024 16:01:00 -0500 A.50202348 CYTO O.40707706 O.48270048 http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html Fri, 04 Oct 2024 16:01:00 -0500 A.50202348 CYTO O.40707706 O.48270048 http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html Fri, 04 Oct 2024 16:01:00 -0500 A.50202348 CYTO O.40707706 O.48270048 http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html Fri, 04 Oct 2024 16:01:00 -0500 A.50202348 CYTO O.40707706 O.48270048 http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html Fri, 04 Oct 2024 16:01:00 -0500 A.50202348 CYTO O.40707706 O.48270048 http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html Fri, 04 Oct 2024 16:01:00 -0500 A.50202348 CYTO O.40707706 O.48270048 http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html <p align="justify">Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. http://www.streetinsider.com/Globe+Newswire/Altamira+Therapeutics+Provides+Update+on+Nasdaq+Listing/23805128.html Fri, 04 Oct 2024 16:01:00 -0500 A.50202348 CYTO O.40707706 O.48270048 http://www.streetinsider.com/Corporate+News/Altamira+Therapeutics+%28CYTO%29+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771189.html <p> </p><ul><li>Certification to ISO 13485 extended to also include production process </li><li>Supports Bentrio growth strategy together with strategic contract manufacturer and expanding network of international distributors</li></ul><p align="justify">Altamira Therapeutics Ltd. (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whole design, development, production and distribution cycle for Altamira Medica’s Bentrio® nasal spray.</p><p align="justify">“We are very proud of passing the required audits for the certification of our quality management system for Bentrio in http://www.streetinsider.com/Corporate+News/Altamira+Therapeutics+%28CYTO%29+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771189.html Fri, 27 Sep 2024 09:01:32 -0500 CYTO http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771180.html <p>Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- </p><ul><li>Certification to ISO 13485 extended to also include production process  </li><li>Supports Bentrio growth strategy together with strategic contract manufacturer and expanding network of international distributors </li></ul> <p align="justify">Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whole design, development, production and distribution cycle for Altamira Medica’s Bentrio® nasal spray. </p> http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771180.html Fri, 27 Sep 2024 09:01:00 -0500 A.41418224 A.50202348 A.60012007 CYTO O.00843119 O.10994612 O.40707706 O.48270048 http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771180.html <p>Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- </p><ul><li>Certification to ISO 13485 extended to also include production process  </li><li>Supports Bentrio growth strategy together with strategic contract manufacturer and expanding network of international distributors </li></ul> <p align="justify">Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whole design, development, production and distribution cycle for Altamira Medica’s Bentrio® nasal spray. </p> http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771180.html Fri, 27 Sep 2024 09:01:00 -0500 A.41418224 A.50202348 A.60012007 CYTO O.00843119 O.10994612 O.40707706 O.48270048 http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771180.html <p>Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- </p><ul><li>Certification to ISO 13485 extended to also include production process  </li><li>Supports Bentrio growth strategy together with strategic contract manufacturer and expanding network of international distributors </li></ul> <p align="justify">Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whole design, development, production and distribution cycle for Altamira Medica’s Bentrio® nasal spray. </p> http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771180.html Fri, 27 Sep 2024 09:01:00 -0500 A.41418224 A.50202348 A.60012007 CYTO O.00843119 O.10994612 O.40707706 O.48270048 http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771180.html <p>Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- </p><ul><li>Certification to ISO 13485 extended to also include production process  </li><li>Supports Bentrio growth strategy together with strategic contract manufacturer and expanding network of international distributors </li></ul> <p align="justify">Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whole design, development, production and distribution cycle for Altamira Medica’s Bentrio® nasal spray. </p> http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771180.html Fri, 27 Sep 2024 09:01:00 -0500 A.41418224 A.50202348 A.60012007 CYTO O.00843119 O.10994612 O.40707706 O.48270048 http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771180.html <p>Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- </p><ul><li>Certification to ISO 13485 extended to also include production process  </li><li>Supports Bentrio growth strategy together with strategic contract manufacturer and expanding network of international distributors </li></ul> <p align="justify">Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whole design, development, production and distribution cycle for Altamira Medica’s Bentrio® nasal spray. </p> http://www.streetinsider.com/Press+Releases/Altamira+Therapeutics+Announces+Extended+ISO+13485+Quality+Management+System+Certification+for+Bentrio+Nasal+Spray/23771180.html Fri, 27 Sep 2024 09:01:00 -0500 A.41418224 A.50202348 A.60012007 CYTO O.00843119 O.10994612 O.40707706 O.48270048